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The immunogenicity and protective capacity of replication-defective herpes simplex virus (HSV) vector-based vaccines were examined in
rhesus macaques. Three macaques were inoculated with recombinant HSV vectors expressing Gag, Env, and a Tat-Rev-Nef fusion protein of
simian immunodeficiency virus (SIV). Three other macaques were primed with recombinant DNA vectors expressing Gag, Env, and a Pol-Tat-
Nef-Vif fusion protein prior to boosting with the HSV vectors. Robust anti-Gag and anti-Env cellular responses were detected in all six macaques.
Following intravenous challenge with wild-type, cloned SIV239, peak and 12-week plasma viremia levels were significantly lower in vaccinated
compared to control macaques. Plasma SIV RNA in vaccinated macaques was inversely correlated with anti-Rev ELISPOT responses on the day
of challenge (P value<0.05), anti-Tat ELISPOT responses at 2 weeks post challenge (P value <0.05) and peak neutralizing antibody titers pre-
challenge (P value 0.06). These findings support continued study of recombinant herpesviruses as a vaccine approach for AIDS.
© 2006 Elsevier Inc. All rights reserved.Keywords: AIDS vaccine; Recombinant HSV vectors; DNA prime; SIV; Rhesus macaqueIntroduction
Development of an effective vaccine against HIV/AIDS
faces a number of severe difficulties (Desrosiers, 2004; Garber
and Feinberg, 2003). In the absence of blind luck in stumbling
upon a successful vaccine, one important obstacle is the lack of
knowledge regarding the characteristics of a protective immune
response that we should be looking for from a vaccine. Once
initial infection is established, HIV has an uncanny ability to
replicate continuously in the face of readily measurable immune
responses to the virus. HIV has evolved a number of specific⁎ Corresponding author. Fax: +1 508 624 8172.
E-mail address: amitinder_kaur@hms.harvard.edu (A. Kaur).
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doi:10.1016/j.virol.2006.08.007immune evasion strategies that allow this continuous, unrelent-
ing viral replication (Desrosiers, 1999). These characteristics
raise concern whether long-lived memory cells that may be
present months or years after immunization can respond in time
to provide sufficient blunting of viral replication during the
initial days and weeks following exposure.
A defining feature of all herpesviruses is that they persist
for the life of the infected individual. Replication-competent
and replication-defective herpesviruses have been used
experimentally as vectors for gene therapy (Burton et al.,
2005) and for vaccine purposes. Vaccine applications of her-
pesvirus vectors have included both AIDS (Murphy et al.,
2000) and non-AIDS (Hoshino et al., 2005; Morrison and
Knipe, 1994; Spector et al., 1998) settings. Herpesvirus vec-
tors may differ fundamentally from other viral vectors that
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(Amara et al., 2001; Dale et al., 2004; Horton et al., 2002;
Pal et al., 2002), adenoviruses (Patterson et al., 2003; Santra et
al., 2005; Shiver et al., 2002) and rhabdoviruses (Ramsburg et
al., 2004; Rose et al., 2001), regarding the nature and
persistence of the immune responses that are generated.
Since herpesviruses may periodically or chronically reactivate,
the numbers of memory cells and the numbers of actively
responding cells at any one time after the last exposure may be
significantly higher than that which is observed with viruses
that do not have the potential to persist. Consequently, we
have been interested in the ability of recombinant herpesvirus-
es to provide vaccine protection against AIDS in an experi-
mental setting.
Here we describe the immune responses and protective
capacity of replication-defective herpes simplex virus (HSV)
vectors with and without prior priming by recombinant DNA.
Results
Experimental design
To improve upon our earlier studies that utilized replication-
competent and replication-defective HSV vectors (Murphy et al.,
2000), we constructed new experimental HSV-SIV vaccines
based on HSV-1 d106, a replication-defective vector with
multiple HSV genes deleted (Samaniego et al., 1998). The lack
of expression of ICP4 and ICP27 prevents the shut-off of host cell
transcription and translation and allows prolonged expression of
the transgene. The lack of host shut-off and early and late HSV
protein synthesis prevents MHC downregulation and ICP47-
associated blockage of the TAP peptide transporter. Separate
HSV-1 d106 vectors were engineered to express gag, env and a
rev–tat–nef fusion protein. High levels of SIV gag and env
expression were achieved by use of codon-modified cassettes
that were modified to achieve maximal levels of expression
(Nasioulas et al., 1994; Schneider et al., 1997; Schwartz et al.,
1992a,b). The nef reading frame in the Tat-Rev-Nef fusion
protein was modified to render it incapable of MHC class I
downregulation (Swigut et al., 2004). This vector expresses
significantly higher levels of SIV protein for more prolonged
periods than we have been able to achieve previously in the
absence of HSV-induced cytopathic effect (Watanabe et al.,
2007).Fig. 1. Schedule of immunizations and SIV challenge in six rhesus macaques. The DN
env, CATEDX gag, CATE239 env and CATEpolNTV. One milligram of each plasm
included three recombinant HSV-1 d106 constructs, d106env, d106gag and d106rev-
the HSV vaccine dose was inoculated via the intramuscular route while one-third of th
of cloned homologous pathogenic SIV239 inoculated via the intravenous route werWe also included a group of monkeys in these studies that
were primed byDNA immunization prior to recombinant HSV-1
d106 immunization. The recombinant DNA constructs that were
used have been described recently (Rosati et al., 2005). Gag and
Env expression plasmids were fused to MCP-3 to facilitate
humoral immune responses. Gag, Env, Pol, Nef, Tat and Vif
genes were fused with the β-catenin peptide in order to target the
viral proteins to the proteasomal degradation pathway and
enhance MHC class I antigen presentation. SIV239 sequences
were used for all immunogen constructions.
One group of three Indian-origin rhesus macaques (Mm 136-
90, 450-91 and 349-91) received the mixture of HSV/SIV
recombinant d106 strains at weeks 0, 4, 12 and 20 (Fig. 1).
Another group of three Indian-origin rhesus macaques (Mm
205-87, 297-91 and 240-91) was immunized with the mixture of
DNAs at weeks 0 and 4 and the mixture of HSV/SIV
recombinant d106 strains at weeks 12 and 20 (Fig. 1). Two
macaques from each group were Mamu-A*01-positive (Mm
136-90, 450-91, 205-87 and 297-91). One macaque (Mm 450-
91) was Mamu-B*17-positive. All of the rhesus monkeys were
obtained from the herpes B-free, specific pathogen free
breeding colony at the NEPRC (Desrosiers, 1997) and were
negative for antibodies to HSVat the time of enrollment. All six
vaccinated monkeys were challenged intravenously with WT
SIV239 at week 26 (Fig. 1).
Antibody responses—vaccine phase
Antibodies to HSV were measured by ELISA using plates
covered with whole lysed HSV virions. All six monkeys were
negative for anti-HSV antibodies at the time of the first im-
munization (Fig. 2A). The three monkeys that received recombi-
nant HSV-SIV d106 at week 0 responded with anti-HSV
antibodies within weeks of this first immunization. Anti-HSV
antibody levels appeared to be boosted in this group of animals
upon each subsequent receipt of recombinant d106 inoculations
(Fig. 2A). The initial inoculations of recombinant DNA, in
contrast, did not result in anti-HSV reactivity in this assay, as
expected. However, inoculation of this group of monkeys with the
HSV-SIVrecombinant d106 strains at week 12 did promptly result
in readily detectable levels of anti-HSV antibodies (Fig. 2A).
These persisted in all six monkeys through challenge.
Antibodies to SIV assayed again by whole virus ELISA
using methodologies that have been extensively described andA immunization consisted of five plasmid constructs: MCP3p39 gag, MCP3p39
id DNA was administered via the intramuscular route. The HSV immunization
tat-nef, each administered at a dose of 1.25 to 3×109 pfu per dose. Two-thirds of
e dose was administered via the subcutaneous route. Ten animal infectious doses
e used for challenge.
Fig. 2. Antibody responses to (A) HSVand (B) SIV in immunized monkeys by
ELISA. Closed symbols denote the DNA–DNA–HSV–HSV vaccinated
macaques, while open symbols denote the HSV–HSV–HSV–HSV vaccinated
macaques. Arrows show the time of vaccination. Anti-HSV antibody responses
in plasma were tested at 1 in 200 dilution, while anti-SIVantibody responses are
shown at 1 in 20 plasma dilutions.
Table 1
Ability of plasma from immunized monkeys to neutralize SIV infectivity
Sample time
(weeks post vaccination)
50% neutralization titers to lab-adapted SIVmac251
Mm
205-87
Mm
297-91
Mm
240-91
Mm
136-90
Mm
450-91
Mm
349-91
0 − a − − − − −
2 − − − − − −
4 − − − − − −
6 − − − − − −
12 − − − <1:20 1:20 1:20
14 1:35 1:80 <1:20 1:30 1:160 1:160
20 − − − 1:20 1:60 1:30
22 1:60 1:60 − 1:30 1:120 1:160
26 b <1:20 <1:20 − − 1:40 1:30
28 c 1:1280 <1:20 1:60 1:480 1:3840 1:2240
34 d 1:1600 1:960 1:2560 nd e 1:7680 1:2560
a ‘−,’ negative.
b Day of SIVmac239 challenge.
c 2 weeks post challenge.
d 8 weeks post challenge.
e nd—not done; Mm136-90 died 3 weeks post challenge.
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were not so readily detected (Fig. 2B). However, anti-SIV
antibodies were measured in all six monkeys with this assay by
2 weeks after the final vaccine boost (Fig. 2B).Fig. 3. Neutralizing antibody responses to laboratory-passaged SIV251 in six vacci
2 weeks post SIV challenge. Serial two-fold dilutions of plasma were incubated with
One pool of negative rhesus monkey plasma was used as a negative control, and two se
time of each assay. In the assays shown 50% neutralizing antibody titers in the positiv
negative.We next measured the ability of plasma to neutralize SIV
infectivity. None of the plasma was able to neutralize infectivity
of SIV239 detectably. This is not surprising because SIV239 is
difficult to neutralize, and even monkeys infected experimen-
tally with SIV239 make neutralizing antibodies of low levels
when measured against this strain (Johnson et al., 2003).
Neutralizing activity was detected, however, when the labora-
tory-passaged, neutralization-sensitive SIV251 strain (SIV251-
lab) was used (Fig. 3A and Table 1). Neutralizing activity against
SIV251-lab was detected at multiple time points in five of the six
monkeys prior to challenge (Table 1). The highest titers ofnated rhesus macaques. (A) At week 26, on day of challenge. (B) At week 28,
SIV251-lab for 1 h before addition of 3×104 CEMx174SIV-SEAP reporter cells.
parate pools of SIV+ rhesus monkey plasma were used as positive controls at the
e pool plasma ranged between 1:3200 and 1:5120. Negative control plasma was
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to challenge were 1:160. This contrasted with titers of 1:3200 to
1:5120 in pooled sera obtained from unvaccinated rhesus
macaques infected with SIV239 and used as a positive control
in the neutralization assay. Thus, the vaccine regimens did
induce neutralizing activity but the titers were low and they did
not detectably neutralize cloned SIV239 whose sequences were
used in the immunogen constructions.
Cellular immune responses—vaccine phase
Cellular immune responses to SIV were measured by the
IFN-γ ELISPOT and ICS assays using overlapping peptides of
individual SIV239 proteins as immunogens. Additionally,
Mamu-A*01/Gag CM9 tetramer-reactive CD8+ T lymphocytes
were measured in the Mamu-A*01-positive rhesus macaques.
IFN-γ ELISPOT responses to the SIV proteins expressed by
both DNA and HSV-1 d106 vectors (Gag, Env, Nef and Tat)
were detected in all six vaccinated monkeys (Fig. 4A). From theFig. 4. Anti-SIV cellular responses during the vaccine phase in immunized monkeys
SIV239 Gag, Env, Nef, Tat and Rev proteins. Closed symbols denote the DNA–DN
HSV–HSV–HSV vaccinated monkeys. Arrows show the time of vaccinations. Spo
unstimulated PBMC in medium alone wells. (B) Frequency of Mamu-A*01/Gag
symbols (left panel) show DNA–DNA–HSV–HSV vaccinated macaques. Open sym
Mamu-A*01-positive rhesus macaques shown. Arrows depict time of vaccination. F
15 min before surface staining with anti-CD3 and anti-CD8 mAb. Data on lymphoc
ELISPOT responses to the Gag CM9 CTL epitope at weeks 14 and 22 during the va
incubated with 10-fold dilutions of SIV Gag CM9 peptide for 16–20 h before measu
CD8+ T lymphocytes is shown. The sensitizing peptide dose required to achieve hatime of the HSV booster inoculation at week 12, the magnitude
of ELISPOT responses to shared SIV immunogens remained
significantly higher in the DNA–DNA–HSV–HSV immunized
macaques compared to the HSV–HSV–HSV–HSV immunized
macaques (Table 2). At its peak, Gag-specific responses as high
as 1442 spot forming cells (SFC)/106 PBMC and Env-specific
responses as high as 3208 SFC/106 PBMC were observed in the
DNA–DNA–HSV–HSV group of rhesus macaques (Fig. 4A).
Such levels are comparable to or higher than those achieved
after wild-type SIV infection of unvaccinated rhesus macaques.
In contrast to Gag and Env, positive ELISPOT responses to the
SIV regulatory proteins Nef, Tat and Rev were of considerably
lower magnitude (Fig. 4A).
Mamu-A*01/Gag CM9 tetramer-reactive CD8+ T lympho-
cytes were detected in all four Mamu-A*01-positive vacci-
nated rhesus macaques and reached a peak level of 2.3% of
CD8+ T lymphocytes in the peripheral blood of Mm 205-87
(Fig. 4B). There was a trend for increasing affinity of Gag
CM9-specific CD8+ T lymphocytes with each HSV booster. (A) IFN-γ ELISPOT responses to pools of overlapping peptides spanning the
A–HSV–HSV vaccinated rhesus macaques. Open symbols denote the HSV–
t forming cell (SFC) frequencies shown after subtraction of background with
CM9 tetramer-positive CD8+ T lymphocytes in immunized monkeys. Closed
bols (right panel) show HSV–HSV–HSV–HSV vaccinated macaques. Data on
resh PBMC were incubated with Mamu-A*01/GagCM9 tetramers at 37 °C for
ytes gated on CD3+CD8+ T lymphocytes shown. (C) Peptide titration of IFN-γ
ccination phase in two Mamu-A*01-positive immunized monkeys. PBMC were
ring IFN-γ ELISPOT responses. Spot forming cell (SFC) frequency per million
lf maximal lysis (SD50) was determined from the titration curves.
Table 2
Pre-challenge cellular immune responses in the two group of vaccinated
macaques
Weeks post
vaccination
Mean (range) SFC/106 PBMCa P value b
DNA–DNA–HSV–HSV
group (n=3)
HSV–HSV–HSV–HSV
group (n=3)
0 c 15 (4–32) 13 (0–30) NS
2 186 (16–390) 317 (34–536) NS
4 c 121 (36–176) 361 (276–488) <0.05
6 514 (462–558) 236 (130–448) <0.05
12 c 181 (88–318) 184 (88–236) NS
14 1389 (1280–1512) 357 (102–818) <0.05
20 c 487 (318–724) 121 (18–236) <0.05
22 1489 (854–2464) 329 (270–412) <0.05
26 d 899 (430–1788) 288 (132–400) <0.05
a Sum of IFN-γ ELISPOT responses to shared SIV immunogens (Gag, Env,
Tat and Nef at all time-points and Rev included after week 12) after subtraction
of background.
b Mann–Whitney U test.
c Times of vaccination.
d Day of challenge.
203A. Kaur et al. / Virology 357 (2007) 199–214inoculation in the DNA primed macaques as evidenced by an
eight-fold or greater decrease in the peptide concentration
required for T cell activation (Fig. 4C). One week after the last
vaccine inoculation (week 21), tetramer-positive CD8+ T
lymphocytes with both effector memory (CD28−, CD62L−,
CCR7−) and central memory (CD28+, CCR7+, CD62L+)
phenotype were observed (Fig. 5 and Table 3). At this time
point, the gut-homing molecule α4β7 was expressed on 13–
50% of tetramer-positive CD8+ T lymphocytes in the
peripheral blood (Table 3). The frequency of Gag CM9
tetramer-reactive CD8+ T lymphocytes correlated positively
with Gag ELISPOT responses, suggesting that a significant
portion of the Gag-specific T lymphocyte response in Mamu-
A*01-positive rhesus macaques consisted of CD8+ T lympho-
cytes responding to the Gag CM9 peptide (Fig. 6A). ELISPOT
responses to the whole SIV239 Gag p55 antigen were also
detected and correlated positively with Gag peptides (Fig. 6B).
Because whole proteins predominantly stimulate CD4+ T
lymphocytes in vitro, the positive p55-specific ELISPOT
response suggested that SIV-specific CD4+ T lymphocytes
were also induced in vaccinated macaques. Induction of both
CD4+ and CD8+ T lymphocyte responses to SIV was
confirmed by the ICS assay (Fig. 7 and Table 4). CD4+ T
lymphocytes responding to SIV Gag and/or Env were detected
in four vaccinated macaques (Table 4).Fig. 5. Phenotype of vaccine-induced Mamu-A*01/Gag CM9 tetramer-positive CD8+
Representative dot plots of four-color flow cytometry gated on CD3+CD8+ T lymp
CM9 tetramer-positive CD8+ T lymphocytes that express the molecule shown on thResults of challenge
All six vaccinated macaques were challenged intravenously
with 10 animal infectious doses of SIV239 at week 26, 6 weeks
after the last vaccine dose (Fig. 1). All vaccinated monkeys
became infected with SIV (Fig. 8). In the vaccinated monkeys,
the median viral load at peak 2 weeks after SIV challenge was
2.4×106 (range 4.0×105 to 2.7×107) plasma SIV RNA
copies/ml; at 12 weeks, it was 8.7×103 copies/ml (range
2.1×102 to 1.3×106 copies/ml); and at 24 weeks it was
1.6×103 copies/ml (range 7.0×101 to 4.5×106 copies/ml).
One HSV–HSV–HSV–HSV vaccinated macaque (Mm 136-
90) died suddenly 3 weeks after SIV inoculation and was likely
a rapid progressor. The set-point plasma SIV RNA at 24 weeks
post SIV challenge in three of the five surviving vaccinated
macaques was <5000 copies/ml (Fig. 8).
To examine whether there was a vaccine effect on control of
viremia, we compared plasma viral load in the vaccinated
macaques with historical controls consisting of 31 unvaccinated
SIV-infected Indian rhesus macaques, 14 from NEPRC and 17
from the Wisconsin Primate Research Center. All had been
inoculated with the same stock of cloned SIV239 used for SIV
challenge in the vaccinated macaques. While there is animal to
animal variation, there have not been changes in the behavior of
this virus stock in groups of unvaccinated control Indian-origin
rhesus macaques over the course of several years. The median
plasma SIV RNA level at peak (week 2) was 0.9 log lower, and
at 12 weeks it was 1.7 log lower in the vaccinated as compared
to the historical control rhesus macaques, and these differences
were statistically significant by the nonparametric Mann–
Whitney U test (Fig. 9). At later time points (20–24 weeks), the
difference in plasma viral load between vaccinated and
historical control macaques failed to reach statistical signifi-
cance (Fig. 9).
Four of six vaccinated macaques (67%) and 23 of 31
controls (74%) were Mamu-A*01-positive (Table 5). Because
the presence of Mamu-A*01 may be an independent predictor
of SIV viral control (Mothe et al., 2003; Muhl et al., 2002; Pal
et al., 2002; Zhang et al., 2002), we compared viral loads in
vaccinated and control macaques stratified on the basis of their
Mamu-A*01 status (Table 5). Vaccinated Mamu-A*01-posi-
tive macaques continued to demonstrate a significant reduction
in peak and 10–14 week time point viral loads as compared to
control Mamu-A*01-positive macaques (Table 5). Although
there was a trend for lower viral loads in vaccinated Mamu-
A*01-positive macaques at 17–28 weeks, this difference didT lymphocytes in the peripheral blood of one immunized monkey (Mm 205-87).
hocytes shown. Percentages in upper right quadrant show the frequency of Gag
e horizontal axis.
Table 3
Phenotype of Mamu-A*01/Gag CM9 tetramer (TM)-positive CD8+ T lymphocytes in the peripheral blood a
Animal Vaccine group % TM+b % Mamu-A*01/CM9 Gag TM+ CD8+ T cells positive for
CD28 CD62L CCR7 α4β7 Ki67 GranB
Mm 205-87 DNA–DNA–HSV–HSV 1.32 50 18 2 13 71 68
Mm 297-91 DNA–DNA–HSV–HSV 0.62 43 23 5 33 65 70
Mm 136-90 HSV–HSV–HSV–HSV 0.10 54 83 42 50 36 42
Mm 450-91 HSV–HSV–HSV–HSV 0.09 43 56 36 50 20 60
a At week 21, 1 week after the last vaccine inoculation.
b Background tetramer staining <0.08% CD8+ T lymphocytes in Mamu-A*01-negative macaques.
Fig. 6. Correlation between IFN-γ ELISPOT responses to SIV Gag peptide pool
and (A) frequency of Mamu-A*01/Gag CM9 tetramer-positive CD8+ T
lymphocytes in Mamu-A*01+ rhesus monkeys and (B) IFN-γ ELISPOT
responses to whole SIV Gag p55 antigen in immunized monkeys.
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one vaccinated macaque (Mm 450-91) contained two MHC
Class I alleles, Mamu-A*01 and Mamu-B*17, a combination
that is particularly associated with low SIV viral loads
(O'Connor et al., 2003). On exclusion of the Mamu-B*17-
positive monkeys (one vaccinated and five controls), the
difference between vaccinees and controls continued to be
statistically significant (P value<0.05) for peak plasma
viremia but did not reach statistical significance (P value
0.07) for the 10–14 week time point. Given the small number
of vaccinated macaques, we cannot definitively evaluate
vaccine efficacy independent of the attenuating effect of
MHC Class I alleles in the current study.
Immune responses post challenge
Neutralizing activity in plasma against SIV251-lab, presum-
ably neutralizing antibodies, increased abruptly in all six animals
following challenge, consistent with the viral load measure-
ments demonstrating that all six vaccinated monkeys had
become infected with SIV (Fig. 3B and Table 1). Neutralizing
activity was dramatically increased in five of the six vaccinated
monkeys by 2 weeks post challenge consistent with an
anamnestic antibody response. Neutralizing activity was not
detected against SIV239 even by 8 weeks post SIV infection.
Dramatic increases in Mamu-A*01/Gag CM9 tetramer-reactive
CD8+ T lymphocytes and ELISPOT responses to Gag, Env and
Nef were observed in all vaccinated macaques in the first 2 to
4 weeks after SIV challenge (Fig. 10A and data not shown).
Since three of the six vaccinated macaques had set-point
plasma SIV RNA levels of <5000 copies/ml, we investigated
whether there was a correlation between vaccination-induced
anti-SIV immune responses and the level of SIV viremia post
challenge. Peak, day of challenge and 2 weeks post challenge
anti-SIV immune responses were examined for inverse correla-
tion with the area under curve (AUC) plasma SIV RNA values
between 0 and 24 weeks of SIV infection (Figs. 10B, C and data
not shown). Although Gag- and Env-specific cellular immune
responses dominated the anti-SIV IFN-γ ELISPOT response
prior to challenge, their magnitude at peak response or at day of
challenge or at 2 weeks post challenge did not correlate with
control of viral load (Figs. 10B, C and data not shown). Instead,
cellular immune responses targeting accessory SIV proteins
appeared to be important. The magnitude of the Rev-specific
IFN-γ ELISPOT response on the day of challenge (Fig. 10B), aswell as the magnitude of the Tat-specific IFN-γ ELISPOT
response 2 weeks post challenge (Fig. 10C) showed a significant
inverse correlation with viral load (Rho −0.86 and −0.87,
respectively, P values<0.05, Spearman Rank Correlation test).
Neutralizing antibody titers on the day of challenge and 2 weeks
post challenge did not correlate significantly with viral load
(Figs. 10B, C). However, the maximal titer of neutralizing
antibodies detected during the vaccine phase showed a strong
trend towards an inverse correlation with AUC plasma SIV
RNA (Rho −0.83, P value 0.06, Spearman Rank Correlation
test; data not shown).
Death of Mm 136-90
One vaccinated macaque, Mm 136-90, died 23 days after
intravenous challenge with SIV239 with no premonitory signs
of illness. Gross and microscopic abnormalities were confined
to the brain. Cut sections of the formalin-fixed brain showed
extensive tan discoloration with multiple red-brown foci
Fig. 7. Detection of CD4+ and CD8+ T lymphocyte responses to SIV in immunized monkeys. Representative intracellular cytokine staining data in one monkey
shown. (A) Gating strategy for analyzing SIV-specific CD4+ and CD8+ T lymphocytes. (B) Responses to SIV Env and Gag in one vaccinated monkey. PBMC were
stimulated for 6 h in the presence of Brefeldin A and evaluated for intracellular cytokine and CD69 expression by four-color flow cytometry. Percentages in upper right
quadrant show the frequency of CD3+8+ or CD4+ T lymphocytes co-expressing CD69 and IFN-γ.
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11A). On light microscopic examination, multiple and randomly
distributed ring hemorrhages and inflammatory cell infiltrates
dotted the otherwise pale white matter; extension into the inner
layers of the gray matter was infrequent (Fig. 11B). On higher
magnification, the white matter was rarefied with angiocentric
hemorrhage and/or inflammatory cell infiltrates (Fig. 11C). At
high magnification, vascular walls were necrotic and surrounded
by degenerate inflammatory cells primarily composed of
neutrophils (Fig. 11D). Sections of the left occipital lobe
immunostained with anti-myelin basic protein showed perivas-
cular loss of myelin (Fig. 11E). Rare glial nodules were
observed within the white matter of the cerebellum and the
corpus striatum (Fig. 11F). The histopathologic findings are
most consistent with a necrotizing and suppurative vasculitis
culminating in secondary ischemic necrosis of the white matter
with perivascular ring hemorrhages and angiocentric loss ofTable 4
Frequencies of CD4+ and CD8+ T lymphocytes responding to SIV Gag and Env pe
Animal a Mamu-A*01 Vaccine
Mm205-87 + DNA–DNA–HSV–HSV
Mm297-91 + DNA–DNA–HSV–HSV
Mm240-91 − DNA–DNA–HSV–HSV
Mm136-90 + HSV–HSV–HSV–HSV
Mm450-91 + HSV–HSV–HSV–HSV
Mm349-91 − HSV–HSV–HSV–HSV
nd—not done.
a Data on week 24 shown.
b Frequency of CD4+ or CD8+ T lymphocytes co-expressing CD69 and interfero
after subtraction of background responses with medium. Responses >0.05% abovemyelin in the foci of inflammation. Light microscopic exa-
mination of multiple sections of the left occipital lobe stained
with H&E, and several special stains did not detect viral
inclusion bodies, protozoa, bacteria, acid fast bacilli or fungal
organisms. A battery of immunohistochemical markers for
herpes simplex virus, cytomegalovirus, adenovirus, SV40 and
SIV did not establish a viral etiology. Furthermore, electron
microscopic examination of several sites from the brain lesion
did not identify an infectious etiology, including herpes
simplex. Co-cultivation of trigeminal and sacral ganglia from
Mm 136-90 onto Vero cells and the E-11 complementing cell
line did not recover any virus.
Discussion
The ability of herpesviruses to persist and induce durable
immune responses in their infected hosts makes them anptides by intracellular cytokine staining assay
% CD4b % CD8
Gag Env Gag Env Gagp11c
0.52 0.53 0.65 0.07 0.68
0.10 0.25 0.32 0.12 nd
nd 0.20 nd 0.02 nd
0.05 nd 0.05 nd 0.06
nd 0 0.05 nd 0.02
0.03 0.06 0.03 0.01 nd
n-γ on 6 h stimulation with SIV peptides. SIV-specific frequencies are shown
background were considered positive.
Fig. 8. Plasma SIV viral loads post intravenous SIV239 challenge in vaccinated
macaques.
Table 5
Comparison of viral load in vaccinated and control Mamu-A*01-positive and
Mamu-A*01-negative rhesus macaques
Group Mamu-A*01
status
Mean plasma SIV RNA copies/ml
Peak (n) a 10–14 weeks (n) 17–28 weeks (n)
Controls Positive 2.2×107 (23) 8.5×105 (22) 2.3×106 (22)
Vaccine Positive 8.0×106 (4) 3.4×104 (3) 9.0×104 (3)
P value b 0.047 c 0.040 c 0.068
Controls Negative 4.2×107 (8) 3.7×107 (8) 9.4×106 (5)
Vaccine Negative 4.4×106 (2) 6.5×105 (2) 2.3×106 (2)
P value 0.037 c 0.117 0.44
a Number of macaques in each group.
b Mann–Whitney U test.
c Significant P value.
206 A. Kaur et al. / Virology 357 (2007) 199–214attractive viral vector for delivery of an AIDS vaccine. We have
previously reported on the efficacy of recombinant replication-
deficient and replication-competent herpes simplex virus
(HSV) vaccine vectors expressing SIV Env and Nef to protect
rhesus macaques against a mucosal challenge with pathogenic
SIV239 (Murphy et al., 2000). Using a new generation of HSV-
SIV recombinants based on the replication-deficient HSV
vector HSV-1 d106 (Samaniego et al., 1998), we now
demonstrate considerable increase in vaccine immunogenicity
as compared to the previous HSV vaccine vectors (Murphy et
al., 2000).
The previous HSV recombinants induced weak humoral and
cellular immune responses against SIV. Binding antibodies were
not readily detected by ELISA-based assays, and neutralizing
activity against lab-adapted SIV251 was not detected (Murphy
et al., 2000). Using the traditional CTL assay, weak CTL activity
was detected at a single time point in only two of seven
immunized monkeys (Murphy et al., 2000). In contrast, the
HSV-1 d106 recombinants used in the current study induced
readily detectable anti-SIV antibodies and a robust cellular
immune response in all six vaccinated monkeys. A single
inoculation of HSV-1 d106 SIV recombinants expressing Gag,
Env and a Rev-Tat-Nef fusion protein was sufficient to induce
anti-SIV T cell responses that were detectable ex vivo by the
IFN-γ ELISPOT assay and by tetramer staining. Vaccination
with recombinant HSV-SIV in the absence of DNA priming gave
rise to peak anti-SIV Tcell responses to the vaccine immunogensFig. 9. Comparison of SIV viral loads in vaccinated rhesus monkeys and unvaccina
Plasma SIV RNA compared in vaccinated and control macaques using the unpairedranging between 528 and 818 SFC/106 PBMC, with more than
half of this response being directed towards the Gag and Env
proteins. These levels are higher or comparable in magnitude to
those induced by several other recombinant viral vector SIV
vaccines in rhesus macaques including attenuated poxviruses,
vaccinia virus, vesicular stomatitis virus, semliki forest virus,
and adeno-associated virus, given alone or in combination with
DNA priming or as heterologous virus boost regimens (Dale et
al., 2004; Doria-Rose et al., 2003; Johnson et al., 2005;
Koopman et al., 2004; Pal et al., 2002; Ramsburg et al., 2004;
Santra et al., 2002). The magnitude of SIV-specific cellular
immune responses in the DNA primed macaques was even
higher and in the range of other highly immunogenic DNA
prime/viral vector boost SIV vaccination regimens in rhesus
macaques consisting of Modified Vaccinia Ankara (MVA) or
replication-deficient Adenovirus Ad5 (Amara et al., 2001;
Casimiro et al., 2003; Horton et al., 2002; Shiver et al., 2002), as
well as with heterologous prime-boost immunization regimen
using MVA and replication-defective Adenovirus vectors
(Casimiro et al., 2004) and replication-competent Adenovirus-
based SIV vaccines (Patterson et al., 2003). Both CD4+ and
CD8+ T lymphocyte responses to SIV were elicited in the
vaccinated macaques. Furthermore, up to 50% of the vaccine-
induced tetramer-positive CD8+ T lymphocytes in peripheral
blood expressed the gut-homing molecule, α4β7, suggesting
that systemic administration of recombinant HSVmay be able to
elicit mucosal immunity. These data are consistent with the
finding of a recombinant NYVAC-SIV vaccine being able to
induce anti-SIV CD8+ T cells in the rectal and vaginal mucosated historical control rhesus macaques infected with the same stock of SIV239.
nonparametric Mann–Whitney U test.
Fig. 10. IFN-γ ELISPOT responses post SIV challenge in vaccinated rhesus macaques. (A) IFN-γ ELISPOT responses to SIV Gag, Env, Nef, Tat and Rev from day of
challenge to week 12 post challenge. Closed symbols show DNA–DNA–HSV–HSV vaccinated macaques, open symbols show HSV–HSV–HSV–HSV vaccinated
macaques. Mm136-90 died 3 weeks post challenge. (B) Regression plots showing relationship between area under curve (AUC) plasma SIV RNA and cellular and
humoral immune responses on the day of challenge. (C) Regression plots showing relationship between AUC plasma SIV RNA and cellular and humoral immune
responses 2 weeks post challenge. AUCwas calculated for plasma SIV RNAvalues until 24 weeks post challenge. Correlation coefficient (Rho) and P values shown in
each plot were calculated by the nonparametric Spearman Rank Correlation test. Plots with an asterisk (*) denote statistically significant correlations. ‘SFC’—spot
forming cells.
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al., 2002). Since mucosal priming can further accentuate
mucosal immunity (Bertley et al., 2004; Egan et al., 2004;
Evans et al., 2003), the ability to deliver recombinant HSV
vectors via mucosal routes may be an added advantage of this
vaccine approach. In all, our finding of robust vaccine-induced
cellular immune responses, combined with the potential of HSV
vectors to elicit durable immune responses and induce mucosal
immunity, makes recombinant HSV-based AIDS vaccine
worthy of further study.
Relative to the magnitude of SIV-specific cellular immune
responses, anti-SIV antibody responses elicited by recombinant
HSV were modest. Binding anti-SIV antibodies were elicited in
all vaccinated macaques, and neutralizing antibodies to the
neutralization-sensitive lab-adapted strain of SIVmac251 were
detected at several time points prior to challenge in five of the six
vaccinated macaques. A similar range of neutralizing antibody
titers to HxB2, a lab isolate of HIV-1, were recently reported in
rhesus macaques immunized with DNA and recombinant
Adenovirus Ad5 vectors encoding HIV Env proteins (Mascola
et al., 2005). The neutralizing antibody titers against lab-adapted
SIVmac251 generated in the immunized macaques in our study
are 100- to 1000-fold lower than following wild-type SIV
infection and at least 10-fold lower than that induced by live
attenuated SIVΔ3 vaccination (Wyand et al., 1999). The low
levels of antibody responses are perhaps not surprising. In SIV
vaccination approaches used thus far in rhesus macaques, high
titer neutralizing antibodies during the vaccination phase have
generally only been seen with regimens that incorporate abooster inoculation of envelope protein (Patterson et al., 2004;
Peng et al., 2005; Zhao et al., 2003), or AT2-inactivated SIV
particles (Willey et al., 2003), and even in these instances
neutralizing antibodies to primary SIV isolates are not detected.
It is of interest that the enhanced immunogenicity of the
current HSV-1 d106 SIV recombinants as compared to the
earlier generation of HSV vectors (Murphy et al., 2000) did not
translate to better protection against SIV239 challenge. In the
previous study, two of seven vaccinated macaques were solidly
protected while one macaque had reduced viral load (Murphy et
al., 2000). In this study, three of six vaccinated macaques had
reduced viral loads. However, both studies differ in important
aspects, particularly with regard to the route of SIV239
challenge (intrarectal versus intravenous), and the timing
between immunization and challenge (22 weeks versus
6 weeks after the last vaccination), making direct comparison
between the two studies difficult. A discrepancy between vac-
cine immunogenicity and protective efficacy was apparent on
analysis of the six vaccinated macaques in this study. Thus, the
magnitude of vaccine-induced SIV-specific cellular immunity to
immunodominant antigens (Gag and Env), as measured by the
frequency of IFN-γ-secreting or tetramer-positive CD8+ T
lymphocytes in peripheral blood, did not correlate with post
challenge viral load. On the contrary, Mm 205-87, the rhesus
macaque with the highest responses during the vaccine phase,
showed no evidence of viral control post challenge. Interest-
ingly, immune parameters that significantly correlated with
lower viral loads post challenge included the presence of Rev-
specific T cell responses on the day of challenge, the rapidity of
Fig. 11. Gross, morphological and immunohistochemical findings in the brain of a rhesusmacaque (136-90) that died 3weeks after SIV challenge. (A)Gross photograph
of the formalin-fixed brain showing tan to brown discoloration of affecting thewhitematter of the left occipital lobe. Compare to normal whitematter on the left (arrows).
Ruler, 1 cm. (B–D) Hematoxylin- and eosin-stained section of the left occipital lobe from the area outlined by the box in panel A. (B) Diffuse pallor of the white matter
due to necrosis with multifocal hemorrhage and basophilic foci composed of inflammatory cell infiltrates. Small foci of hemorrhage and inflammatory infiltrates extend
into the inner layer of the gray matter. Arrow marks interface of gray and white matter. (C) Higher magnification of white matter showing foci of hemorrhage and
inflammatory cell infiltrates. Rarefaction of white matter is evident. (D) Higher magnification illustrating necrosis of a blood vessel surrounded by infiltrates of
degenerate neutrophils.Magnifications, ×20 (b), ×100 (c) and ×400 (d). (E) Immunohistochemical staining for myelin basic protein (MBP) of occipital cortex. Pallor or
lack of staining for MBP corresponds to destruction of myelin in areas of perivascular neutrophilic infiltrates and vascular necrosis as depicted in (B–D).Magnification,
×20 (E). (F) Hematoxylin- and eosin-stained section of cerebellar white matter showing a glial nodule. Magnification ×200 (F).
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challenge and the magnitude of neutralizing antibody activity
prior to challenge. These findings suggest that a successful AIDS
vaccine may need to prime for Tcell responses to accessory HIV
proteins in addition to inducing neutralizing antibodies.
The vaccinated monkey that died 3 weeks after SIV
challenge, likely a rapid progressor, had a unilateral lesion in
the left occipital lobe. The microscopic findings were character-
ized by a necrotizing and suppurative vasculitis with secondary
necrosis of the white matter. In addition, rare glial nodules were
present in the cerebral white matter and brainstem but were
unrelated to the occipital lobe lesion. Glial nodules are
nonspecific lesions that usually result from viral infection (An
et al., 2002; Prineas et al., 2002); in this case, the nodules were
negative by IHC for viruses, including SIV, and of unknownsignificance. Differential diagnoses for the occipital lobe lesion
included a septic lesion of hematogenous origin (Kennedy,
2004; Moore, 2000), HSV encephalitis (Kennedy, 2004, 2005)
and acute hemorrhagic leukoencephalitis (AHL). An extensive
histopathologic workup failed to identify an infectious etiology,
including HSV, as the cause of the vasculitis. Encephalitis
related to reversion of the replication-deficient HSV vaccine to
replication-competent HSV was considered unlikely for several
reasons. In vivo replication of HSV-1 d106 vectors could
hypothetically occur in two scenarios; one, in the presence of
host cellular proteins able to compensate for the deleted
immediate early HSV genes; and two, by recombination with
herpes B virus naturally infecting rhesus macaques. Rhesus
macaques in this study were seronegative for herpes B. Although
a seronegative status for herpes B does not preclude herpes B
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herpes virions by electron microscopy and herpes antigen by
immunohistochemistry makes the diagnosis of HSVencephalitis
highly unlikely. In the absence of an infectious etiology, the
morphologic changes of perivascular hemorrhages, perivascular
myelinolysis and neutrophilic infiltration in the white matter are
consistent with a diagnosis of AHL as the cause of the
encephalitis (An et al., 2002; Bennetto and Scolding, 2004;
Hart and Earle, 1975; Prineas et al., 2002). AHL is a rare,
fulminant and often fatal disorder of unknown etiology that is
thought to be immune-mediated or a sequela of the acute
perivascular inflammation (Bennetto and Scolding, 2004; Hart
and Earle, 1975; Prineas et al., 2002). A febrile or nonspecific
respiratory infection often precedes onset of both AHL and
postinfectious encephalitis with a temporal relationship of 1 to
4 weeks between the precipitating cause and onset of neurologic
disease. While there was a temporal relationship (3 weeks)
between experimental SIV infection and death, it cannot be
ascertained that SIV was the precipitating cause. Finally, the
morphology of the lesion and the long interval (8 weeks)
between the last vaccination and death argue against a diagnosis
of postvaccinal encephalomyelitis.
In this study, historical controls were used for assessment of
vaccine efficacy. Although not ideal, the use of historical
controls allowed us to include a large number of animals that
would not otherwise have been possible with concurrent con-
trols. The historical controls consisted of 31 SIV naive rhesus
macaques that had been infected with the same challenge stock
of SIV239 that was used for infecting the vaccinated macaques
in the present study. Peak height and set-point viral loads with
this SIV239 are reasonably consistent from animal-to-animal
and study-to-study (Johnson et al., 2003). Furthermore, we were
able to compare the vaccinated and control groups as a whole as
well as stratified based on theirMamu-A*01 status. A significant
vaccine effect on viral load persisted even when only the Mamu-
A*01-positive macaques were examined. Although these results
are encouraging, the small number of vaccinated macaques in
the current study precludes definitive conclusion of vaccine
efficacy independent of other attenuating MHC Class I alleles
such as Mamu-B*17 and Mamu-A*1303 (Muhl et al., 2002;
O'Connor et al., 2003). Furthermore, relative efficacy of the two
vaccine approaches cannot be assessed with the small number of
vaccinated monkeys in this study.
It is somewhat disappointing that stronger levels of protection
were not observed in these experiments, particularly given the
breadth and nature of the immune responses that were generated
by the vaccines. The disappointing levels of protection occurred
despite attempts to use unrealistic vaccine/challenge conditions
that favor the possibility of protection. The challenge virus,
SIV239, is not only a homogeneous clone, it is exactly matched
in sequence to the sequences present in the vaccine. Further-
more, challenge occurred 6 weeks after the fourth vaccine
administration. The challenge virus, like primary isolates of
HIV-1, principally uses CCR5 as its second receptor, is difficult
to neutralize and induces a chronic, progressive disease course
following long-term persistent infection. It could be argued that
IV inoculation of 10 monkey infectious doses may beuncharacteristically higher than the 1–2 infectious doses that
typify natural infection. However, in the absence of sterilizing
immunity, it is still disappointing that the cellular responses
could not do a more effective job in controlling the sequence-
matched challenge virus. It seems likely that a vaccine will need
to be able to provide much better levels of protection against
homologous SIV239 challenge to have any hope of working in
human field trials. Among factors that could improve protective
efficacy are efficient induction of mucosal immunity, induction
of long-lived memory T cells with good proliferative capacity,
i.e., central memory T cells (Vaccari et al., 2005; Wherry et al.,
2003), and induction of higher levels of potently neutralizing
antibodies. In DNA/viral vector vaccine approaches, priming
with viral vector via the mucosal route followed by systemic
administration of DNA can induce excellent mucosal and
systemic Tcell and humoral immune responses (Eo et al., 2001).
Whether priming with recombinant HSV via the mucosal route
will similarly improve induction of mucosal immunity and
improve protective efficacy against the AIDS virus remains to be
determined.
Materials and methods
DNA plasmids
The plasmids used for DNA vaccination contain the CMV
promoter without an intron, the bovine growth hormone
polyadenylation site and the kanamycin resistant gene. The
RNA (codon) optimized SIV genes were generated introducing
multiple silent point mutations not affecting the sequence of the
encoded proteins, as previously described for HIV-1 gag and
env (Nasioulas et al., 1994; Schneider et al., 1997; Schwartz
et al., 1992a,b) using synthetic DNAs. The secreted and
intracellularly degraded variants of the SIV antigens were
generated by fusion of either IP10-MCP3 or of a beta-catenin
(CATE)-derived peptide, respectively, at the N-terminus of Gag
and Env, as previously described (Rosati et al., 2005) or by
fusion of the CATE-derived peptide to polNTV, encoding a
fusion protein comprising of an inactive pol, nef, tat and vif
(von Gegerfelt et al., in preparation).
Recombinant HSV vaccine
HSV recombinant vectors were constructed in the HSV-1
d106 mutant strains (Samaniego et al., 1998). HSV-1 d106
contains mutations that inactivate expression of four immediate
early genes, ICP4, ICP27, ICP22 and ICP47, and thus was
grown in the E-11 cell line containing the ICP4 and ICP27 genes.
The vaccine vector properties of d106 and the isolation of d106
based recombinant vectors expressing SIV env, SIV gag and a
rev-tat-nef fusion protein is described elsewhere (Watanabe
et al., 2007). Expression cassettes for SIV env and SIV gag
utilized RNA-optimized ORFs described above, and the rev-
tat-nef cassette was constructed from sequences in the
p239SpE3′/nef-open plasmid (Regier and Desrosiers, 1990)
and the nefΔ plasmid (Kestler et al., 1990). The expression
cassettes were inserted into transfer plasmids and recombined
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homologous recombination. Stocks for the immunization
studies were prepared by growth on the E-11 complementing
cell line.
Animals, vaccine regimen and SIV challenge
Six Indian rhesusmacaques housed in the herpesB-free specific
pathogen free colony of theNewEngland PrimateResearchCenter
(NEPRC) were enrolled in the study. Animals were maintained in
accordance with federal and institutional guidelines mandated by
the Animal Care and Use Committee of Harvard Medical School.
Three rhesus macaques received a DNA prime, recombinant HSV
boost vaccine regimen (Group DNA–DNA–HSV–HSV) while
three rhesus macaques were only vaccinated with recombinant
HSV (Group HSV–HSV–HSV–HSV).
The vaccine regimen consisted of four inoculations
administered at 0, 4, 12 and 20 weeks (Fig. 1). The DNA
inoculum included five plasmid DNA constructs: MCP3p39
gag, MCP3p39 env, CATEDX gag, CATE239 env and
CATEpolNTV. One milligram of each plasmid DNA (total
5 mg DNA) was injected at two to three sites via the
intramuscular route. The HSV d106 vaccine inoculum
included three recombinant HSV constructs, d106env,
d106gag and d106rev-tat-nef, each administered at a dose of
1.25 to 3×109 pfu per dose. Two-thirds of the HSV vaccine
dose was inoculated via the intramuscular route, while one-
third of the dose was administered via the subcutaneous route.
All six vaccinated animals were challenged at 26 weeks with
10 animal infectious doses of cloned homologous pathogenic
SIV239 via the intravenous route.
Analysis of humoral immunity
ELISA plates for HSV were obtained commercially (Viral
Antigens, Memphis TN); SIV ELISA plates were constructed as
previously described (Daniel et al., 1988; Wyand et al., 1996).
Serum was assayed at a dilution of 1:20 or 1:200 in phosphate
buffered saline (PBS)–Tween20 0.05% supplemented with 5%
inactivated goat serum or 5% inactivated fetal bovine serum for
the SIVand HSV ELISA, respectively. Plates were incubated at
room temperature for 1 h, washed three times with PBS–
Tween20 0.05% and incubated with 100 μl diluted goat anti-
human IgG-conjugated alkaline phosphatase (Kirkegaard and
Perry Laboratories, Gaithersburg, MD). Following a 1 h in-
cubation at room temperature, plates were washed three times
and color was developed at room temperature with 200 μl
p-nitrophenyl substrate solution (KPL) per well. After 30 min,
the color reaction was stopped by the addition of 50 μl 3 N
NaOH per well, and absorbance was determined at 410 nm on a
microplate reader (Dynex Technologies, Chantilly, VA).
Neutralizing antibody titers to SIV239 and lab-passaged
SIV251-lab were determined by the ability to block infection
of CEMx174SIV-SEAP cells harboring a Tat-inducible SEAP
reporter construct as described previously (Means et al.,
1997). Serial two-fold dilutions of plasma were incubated
with virus at 100 μl per well in 96-well plates for 1 h prior toaddition of 3×104 CEMx174SIV-SEAP cells (100 μl) for a
final volume of 200 μl per well. After 72 h, 18 μl of
supernatant was removed and assayed for SEAP activity
using the Phospha-Light SEAP detection kit (Applied
Biosystems, Foster City, CA) according to manufacturer's
instructions, with analysis on a Wallac multilabel microplate
reader (Perkin Elmer, Boston, MA). Control wells for mock-
infected cells and virus treated with pooled SIV-negative
plasma were used to determine background and maximal
SEAP production, respectively. The percent neutralization was
calculated from the mean SEAP counts at each plasma
dilution divided by the maximal SEAP counts after subtract-
ing background activity. Fifty percent neutralization titers
were calculated as the reciprocal of the plasma dilution at
which infectivity was reduced by 50%.
Antibodies for flow cytometry
The following anti-human monoclonal antibodies (mAbs)
were obtained from BD Biosciences Pharmingen (San Jose,
CA) unless otherwise indicated: anti-CD3 (clone SP34)
fluorescein isothiocyanate (FITC) or phycoerythrin (PE),
anti-CD4 (clone L200) allophycocyanin (APC), anti-CD8
(clone SK1) peridinin chlorophyll protein (PerCP), anti-
CD11a (clone H111) FITC, anti-CD28 (clone CD28.2)
FITC or PE, anti-CD62L-selection (clone SK11) PE, anti-
β7 integrin (clone FIB 504) PE, anti-CCR7 (clone 150503,
R&D System, Inc., Minneapolis, MN) PE and α4β7 (clone
ACT-1; a gift from Leukosite, Inc.) PE. Anti-IFN-γ (clone
B27) APC or FITC, anti-TNF-α (clone Mab11) APC or
FITC, anti-CD69 (clone FN50) PE, anti-Granzyme B (clone
GB12) PE and anti-Ki67 (clone B56) FITC were used for
intracellular staining. Purified anti-CD28 (clone 28.2, 10 μg/
ml) and anti-CD49d (clone 9F10, 10 μg/ml) were used for
costimulation in cytokine staining assays (ICS). Affinity-
purified F(ab′)2 fragments of goat anti-mouse IgG (H+L)
(GAM, Kirkegaard and Perry laboratories, Gaithersburg, MD)
were used for cross-linking the costimulatory antibodies in
ICS assays.
SIV antigens
Fifteen amino acid (aa) long peptides with 11 aa overlaps
spanning the entire SIV239 proteome were obtained through the
NIH AIDS Research and Reference Reagent program and
synthesized at the Massachusetts General Hospital peptide core
facility (Charlestown, MA) by F-moc chemistry using an auto-
mated peptide synthesizer (MBS 396; Advanced Chemtech,
Inc., Louisville, KY). Peptide pools for individual SIV proteins
were made up and used for stimulation in ELISPOT and ICS
assays. The individual peptide concentration used for stimula-
tion ranged between 1 and 2 μg/ml. SIVmac251 P55 Gag
antigen derived from the supernatant of baculovirus was
obtained from Quality Biological, Inc (QBI, Gaithersburg,
MD) through the Vaccine Research and Development Branch,
Division of AIDS, NIAID, NIH and used at 5 μg/ml for
stimulation.
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Three complementary assays, the interferon-γ (INF-γ)
ELISPOT assay, intracellular cytokine staining (ICS) assay
and MHC tetramer analysis, were used for quantitation and
phenotypic characterization of SIV-specific CD4+ and CD8+ T
lymphocytes.
(i) IFN-γELISPOTwas performed on PBMC freshly isolated
from heparinized blood by density gradient centrifugation over
Ficoll-Hypaque (ICN Biomedicals Inc, Aurora, OH). PBMC
were suspended in RPMI (Gibco/Invitrogen Corp., Carlsbad,
CA) containing 2 mM L-glutamine (Gibco/Invitrogen), 10 mM
HEPES buffer (Gibco/Invitrogen), 10% fetal bovine serum
(Sigma Aldrich, St. Louis, MO) and 50 IU/ml each of penicillin
and streptomycin (henceforth referred to as R-10 medium) and
placed in wells of a 96-well polyvinylidene difluoridemembrane
bottom ELISPOT plate (Millipore, Bedford, MA) coated with
the anti-human IFN-γ monoclonal antibody (mAb) clone GZ-4
(Mabtech, Sweden) alongwith SIV peptides or p55 antigen or R-
10 medium. After overnight incubation at 37 °C in a 5% CO2
incubator, cells were removed by extensive washing and the
wells incubated serially with biotinylated anti-human IFN-γ
mAb clone 7-B6-1 (Mabtech, Sweden) followed by streptavidin/
alkaline phosphatase. Spots were developed by addition of
alkaline phosphatase conjugate substrates nitro blue tetrazolium
(NBT)/5-bromo-4-chloro-3-indolyl phosphate (BCIP) in color
development buffer (Biorad, Hercules, CA). Spots were counted
with a KS ELISPOT Automated Reader (Carl Zeiss Inc,
Thornwood, NY) using KS ELISPOT software 4.5 (performed
by Zellnet Consulting, Inc., Fort Lee, NJ). Cut-off values for
positive SIV-specific ELISPOT responses were established by
testing responses to SIV peptide pools in SIV-negative rhesus
macaques. Using a negative cut-off value of three standard
deviations above the mean in SIV-negative rhesus macaques,
spot frequencies greater than 50 spot forming cells (SFC)/106
PBMC after subtraction of background were considered
positive.
(ii) Intracellular cytokine staining (ICS) was performed on
cryopreserved PBMC using a protocol optimized for rhesus
macaques as previously described (Kaur et al., 2002). Briefly,
PBMC were stimulated with 1–2 μg/ml of peptides in the
presence of 10 μg/ml each of costimulatory mAbs anti-CD28
and anti-CD49d which had been cross-linked to affinity purified
F (ab′)2 fragments of goat anti-mouse IgG (Kirkegaard and
Perry laboratories Inc., Gaithersburg, MD). Stimulation was
performed for 6 h at 37 °C in a 5% CO2 incubator in polytyrene
tubes placed 5° above horizontal, and Brefeldin A (10 μg/ml)
was added for the final 5 h of stimulation. At the end of
stimulation, cells were washed, incubated with 0.02% EDTA for
15 min, washed and then surface stained with anti-CD3 and
anti-CD8 mAb for 39 min at 4 °C. After surface staining, cells
were subjected sequentially to fixation and permeabilization
using a commercial medium (FIX and PERMMedium A and B;
Caltag Labs, Burlingame, CA). Permeabilized cells were
incubated with anti-CD69 and anti-IFN-γ at room temperature
for 29 min for intracellular staining. After washing, cells were
kept overnight at 4 °C in fresh 2% paraformaldehyde. At least200,000 events were collected on a FACSCalibur (BD
Bioscience) and data analyzed using CELLQuest software
(BD Biosciences).
(iii) Mamu-A*01/CM9 Gag tetramer analysis was performed
on whole blood using four-color flow cytometry. Freshly drawn
heparin blood (100 μl) was incubated with the tetramer APC
conjugate for 15 min at 37 °C and followed by surface staining
with anti-CD3, anti-CD8 and additional antibodies for pheno-
typic characterization. After surface staining, cells were washed
and red cells lysed with FACSLyse solution (BD Biosciences).
Washed cells were fixed overnight in 2% paraformaldehyde at 4
°C. At least 200,000 events were collected on a FACSCalibur
and data analyzed with CELLQuest software.
MHC typing
DNA was extracted from PBMC or B-lymphoblastoid cell
lines using the QIAamp DNA blood kit (Qiagen, Valencia, CA)
and subjected to PCR with rhesus macaque MHC Class I
sequence specific primers for Mamu-A*01 and Mamu-B*17 as
described (Knapp et al., 1997; Muhl et al., 2002).
Measurement of plasma SIV RNA
Blood collected in tubes containing EDTA was spun at
2000 rpm for 10 min within 3 h of drawing blood and stored at
−80 °C for quantitation of SIV RNA. SIV RNAwas quantified
using a real time RT PCR assay, as previously described (Cline et
al., 2005). As used in the present study, the assay has a threshold
sensitivity of 10 SIV gag RNA Copy Eq/ml of plasma.
HSV isolation
Trigeminal and sacral ganglia obtained at necropsy were
minced and co-cultured onto Vero cells and the E-11 com-
plementing cell line. Co-cultures were visually monitored twice
daily for 1 week for evidence of cytopathic effects.
Histopathologic examination
At necropsy, 5-μ sections of formalin-fixed, paraffin-em-
bedded tissues were stained with hematoxylin and eosin. Special
stains included: Brown and Brenn Gram, modified Steiner's
silver, Ziehl-Neelsen acid fast, Grocott's methenamine silver
and periodic acid–Schiff. Monoclonal antibodies used for
immunohistochemistry included: anti-SIVnef (clone KK75,
Centralised Facility for AIDS Reagents, National Institute for
Biological Standards and Control, Potters Bar, U.K.), anti-
HIV1-p24/SIVp27 (clone 183-H12-5C, NIH AIDS Research
and Reference Reagent Program, Germantown, MD), anti-
SV40TAg Ab-2 (clone PAb416, Oncogene, Boston, MA), anti-
adenovirus (clone 20/11, Chemicon, Temecula, CA); polyclonal
antibodies included: anti-rhesus cytomegalovirus IE1 (gift from
Dr. Peter Barry, University of California, Davis), anti-human
myelin basic protein (Dako, Carpinteria, CA) and anti-herpes
simplex virus 1 (Dako), which also immunolabels herpes B.
Five-μ sections of paraffin-embedded sections of the left
212 A. Kaur et al. / Virology 357 (2007) 199–214occipital lobe were deparaffinized and rehydrated, and hydrogen
peroxide was applied for 5 min to quench endogenous
peroxidase. Antigen retrieval was achieved by microwaving
for 20 min in citrate buffer with the exceptions of anti-
adenovirus, which was treated with proteinase K for 5 min, and
anti-herpes simplex, which required no antigen retrieval. Dako
Protein Block was applied for 10 min, and duplicate sections
were incubated with either the primary antibody or the
appropriate irrelevant antibody for negative controls (irrelevant
IgG1 for monoclonal antibodies, and anti-rabbit immunoglobu-
lin fraction for polyclonal antibodies). Next, biotin block was
applied for 20 min followed by incubation with the secondary
antibody (biotinylated horse anti-mouse for monoclonal anti-
bodies and biotinylated goat anti-rabbit for polyclonal anti-
bodies) for 30 min. Vectastatin avidin–biotin complex (Vector,
Burlingame, CA) was applied for 30 min, and the reaction was
visualized with DAB chromogen (Dako) and counterstained
with Mayer's hematoxylin.
Electron microscopy
Formalin-fixed tissue from the left occipital lobe was pro-
cessed for electron microscopy. Specimens were washed in
0.1 M phosphate buffer and postfixed in 1% osmium tetroxide.
The specimens were dehydrated, embedded in Epon araldite and
stained with uranyl acetate and Sato's lead stain for examination
using a Jeol 1010 Electron Microscope (Jeol, Tokyo, Japan).
Statistical analysis
Statistical analysis was performed using Statview software
(Abacus Concepts, Inc., Berkeley, CA). The nonparametric
Mann–Whitney U test was used for comparison of unpaired
groups. Correlations between viral load and immune parameters
were performed by the Spearman Rank Correlation test. Area
under curve (AUC) for plasma SIV RNA was calculated using
the GraphPad Prism software (GraphPad software Inc., San
Diego, CA).
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